Cargando…
Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development
Infection with nontuberculous mycobacteria (NTM) is a complication of lung disease in immunocompromised patients, including those with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The most wid...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406338/ https://www.ncbi.nlm.nih.gov/pubmed/30717247 http://dx.doi.org/10.3390/microorganisms7020042 |
_version_ | 1783401278279254016 |
---|---|
author | Auster, Lauren Sutton, Morgan Gwin, Mary Chandler Nitkin, Christopher Bonfield, Tracey L. |
author_facet | Auster, Lauren Sutton, Morgan Gwin, Mary Chandler Nitkin, Christopher Bonfield, Tracey L. |
author_sort | Auster, Lauren |
collection | PubMed |
description | Infection with nontuberculous mycobacteria (NTM) is a complication of lung disease in immunocompromised patients, including those with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The most widespread, disease-causing NTM is Mycobacterium avium complex (MAC), which colonizes the lungs as a combination of Mycobacterium avium, Mycobacterium intracellulare, and other mycobacterial species. While combination drug therapy exists for MAC colonization, there is no cure. Therapeutic development to treat MAC has been difficult because of the slow-growing nature of the bacterial complex, limiting the ability to characterize the bacteria’s growth in response to new therapeutics. The development of a technology that allows observation of both the MAC predominant strains and MAC could provide a means to develop new therapeutics to treat NTM. We have developed a new methodology in which M. avium and M. intracellulare can be optimally grown in short term culture to study each strain independently and in combination, as a monitor of growth kinetics and efficient therapeutic testing protocols. |
format | Online Article Text |
id | pubmed-6406338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64063382019-03-26 Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development Auster, Lauren Sutton, Morgan Gwin, Mary Chandler Nitkin, Christopher Bonfield, Tracey L. Microorganisms Article Infection with nontuberculous mycobacteria (NTM) is a complication of lung disease in immunocompromised patients, including those with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The most widespread, disease-causing NTM is Mycobacterium avium complex (MAC), which colonizes the lungs as a combination of Mycobacterium avium, Mycobacterium intracellulare, and other mycobacterial species. While combination drug therapy exists for MAC colonization, there is no cure. Therapeutic development to treat MAC has been difficult because of the slow-growing nature of the bacterial complex, limiting the ability to characterize the bacteria’s growth in response to new therapeutics. The development of a technology that allows observation of both the MAC predominant strains and MAC could provide a means to develop new therapeutics to treat NTM. We have developed a new methodology in which M. avium and M. intracellulare can be optimally grown in short term culture to study each strain independently and in combination, as a monitor of growth kinetics and efficient therapeutic testing protocols. MDPI 2019-02-01 /pmc/articles/PMC6406338/ /pubmed/30717247 http://dx.doi.org/10.3390/microorganisms7020042 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Auster, Lauren Sutton, Morgan Gwin, Mary Chandler Nitkin, Christopher Bonfield, Tracey L. Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development |
title | Optimization of In Vitro Mycobacterium avium and Mycobacterium
intracellulare Growth Assays for Therapeutic Development |
title_full | Optimization of In Vitro Mycobacterium avium and Mycobacterium
intracellulare Growth Assays for Therapeutic Development |
title_fullStr | Optimization of In Vitro Mycobacterium avium and Mycobacterium
intracellulare Growth Assays for Therapeutic Development |
title_full_unstemmed | Optimization of In Vitro Mycobacterium avium and Mycobacterium
intracellulare Growth Assays for Therapeutic Development |
title_short | Optimization of In Vitro Mycobacterium avium and Mycobacterium
intracellulare Growth Assays for Therapeutic Development |
title_sort | optimization of in vitro mycobacterium avium and mycobacterium
intracellulare growth assays for therapeutic development |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406338/ https://www.ncbi.nlm.nih.gov/pubmed/30717247 http://dx.doi.org/10.3390/microorganisms7020042 |
work_keys_str_mv | AT austerlauren optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment AT suttonmorgan optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment AT gwinmarychandler optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment AT nitkinchristopher optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment AT bonfieldtraceyl optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment |